Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia [PDF]
Biology, 2023 Background. Patients with β-thalassemia have a high incidence of atrial fibrillation (AF) and other supraventricular arrhythmias. The use of non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prophylaxis in patients with β ...
Michele Malagù +8 more
doaj +4 more sources
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. [PDF]
Thromb Haemost, 2023 Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due to interactions or reduced adherence, but comparative data are lacking ...
Grymonprez M +4 more
europepmc +2 more sources
Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study. [PDF]
Eur Heart J Qual Care Clin Outcomes, 2023 Aims Data on non-vitamin K antagonist oral anticoagulants (NOACs) use in patients with atrial fibrillation (AF) and frailty are scarce. Therefore, the impact of frailty on AF-related outcomes and benefit–risk profiles of NOACs in patients with frailty ...
Grymonprez M +4 more
europepmc +2 more sources
Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial. [PDF]
Stroke, 2023 BACKGROUND: Evidence-based hemostatic treatment for intracerebral hemorrhage (ICH) associated with non–vitamin K antagonist oral anticoagulants (NOACs) is lacking. Tranexamic acid (TXA) is an antifibrinolytic drug potentially limiting hematoma expansion.
Polymeris AA +28 more
europepmc +2 more sources
Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. [PDF]
Heart, 2023 Objective There has been limited systematic evaluation of outcomes and drivers of inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients with atrial fibrillation (AF).
Caso V +13 more
europepmc +2 more sources
Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [PDF]
The Korean Journal of Internal Medicine, 2023 In the last decade, non-vitamin K antagonist oral anticoagulants (NOACs), a new generation of OACs, were introduced to prevent thromboembolism in patients with atrial fibrillation.
Ki Hong Lee, Hyung Wook Park
doaj +2 more sources
Comparison of ََQuality of Life and Treatment Satisfaction among Sample of Iraqi Patients Using Anticoagulant Therapy (Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants) [PDF]
مجلة كلية الطبBackground: Oral anticoagulation medication, warfarin and non-vitamin k antagonist oral anticoagulants (NOAC) may require long term use which may affect patients’ satisfaction with their treatment and their quality of life (QOL). Objective: To compare
Basma Z. Al-Metwali, Tuqa M. AL-Ameen
doaj +3 more sources
Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. [PDF]
Critical Care, 2015 Perioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge. Due to the lack of good clinical studies involving adequate monitoring and reversal therapies, management requires knowledge and ...
Albaladejo, Pierre +4 more
core +4 more sources
Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants. [PDF]
Open Heart, 2018 Randomised controlled trials (RCTs) provide the reference standard for comparing the efficacy of one therapy or intervention with another. However, RCTs have restrictive inclusion and exclusion criteria; thus, they are not fully representative of an ...
Camm, AJ, Fox, KAA
core +2 more sources
Preparation and Characterization of Isradipine as Surfactant-Free Dry Emulsion [PDF]
مجلة كلية الطبBackground: Oral anticoagulation medication, warfarin, and non-vitamin K antagonist oral anticoagulants (NOAC) may require long-term use which may affect patients’ satisfaction with their treatment and their quality of life (QOL).
Zahraa M. Al-Sharify, Fatima J. Jawad
doaj +3 more sources